NCT05543681: IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's |
|
|
| Recruiting | 2 | 164 | Canada, US | Agitation management in Alzheimer's disease (IGC-AD1-Active), Active Study Drug, Study Drug, Active, IGC-AD1 Active, Agitation management in Alzheimer's disease (IGC-AD1-Placebo), IGC-AD1 Placebo, Non-active study drug, IGC-AD1 Non-Active, Placebo | IGC Pharma LLC | Alzheimer Disease, Agitation,Psychomotor, Depression, Anxiety, Memory Impairment, Care Giving Burden, NPS, Agitated; State, Acute Reaction to Stress, Aggression, Aggressive Outburst | 06/25 | 06/25 | | |
NCT05669014: A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM) |
|
|
| Recruiting | 2 | 96 | Europe, US, RoW | Daxdilimab, HZN-7734, Placebo | Amgen | Idiopathic Inflammatory Myositis | 10/26 | 05/27 | | |
NCT05046158: Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care |
|
|
| Recruiting | N/A | 200 | US | Transforming Powder Dressing, Altrazeal, Standard of care topical wound agents and dressings | ULURU Inc., Naval Medical Research Center, Military Technology Enterprise Consortium (US) | Diabetic Foot Ulcer | 12/23 | 12/23 | | |
